Elevance Health, Inc. (NYSE:ELV) is one of the Best Undervalued Stocks to Buy According to the Financial Media. On May 19, Evercore ISI added the company to its Tactical Outperform list for Q2, noting that Elevance Health, Inc. (NYSE:ELV) is expected to see strong upside in EPS this year, provided current trends hold or improve.
That being said, the analyst did not upgrade the shares. This is because the firm is concerned about the potential for Medicaid to encounter some headwinds in 2027 from OBBBA work requirements, added the analyst. The firm has an “In Line” rating and a price objective of $360.
Notably, Elevance Health, Inc. (NYSE:ELV)’s Q1 2026 results surpassed expectations, demonstrating underlying business strength and improving claims experience. The company’s operating revenue came in at $49.5 billion in Q1 2026, implying a $0.7 billion or 1.5% rise versus Q1 2025. This was because of increased premium yields in the Health Benefits segment and growth in CarelonRx product revenue.
Elevance Health, Inc. (NYSE:ELV) operates as a health benefits company.
While we acknowledge the potential of ELV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 10 Best FMCG Stocks to Invest In According to Analysts and 11 Best Long-Term Tech Stocks to Buy According to Analysts.
Disclosure: None. Follow Insider Monkey on Google News.
